CFI-400945 - Moligand™, ≥97% , Inhibitor of polo like kinase 4, CAS No.1338806-73-7, Inhibitor of polo like kinase 4

CAS: 1338806-73-7 Cat. No.: C413779 Formule: C33H34N4O3 Poids moléculaire: 534.65 PubChem CID: 58486178
DISPONIBLE À COMMANDE
QUALITÉ & PURETÉ Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. ≥97%
Synonyms
CFI-400945 (free base)|(1R,2S)-2-(3-((E)-4-(((2R,6S)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one|(1r,2s)-2-(3-((e)-4-(((2r,6s)-2,6-dimethyl morpholino)methyl)styryl)-1h-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one|Spiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one, 2-[3-[(1E)-2-[4-[[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5'-methoxy-, (1R,2S)-|ocifisertib [INN]|(2'S,3R)-2'-[3-[(E)-2-[4-[[(2S,6R)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5-methoxyspiro[1H-indole-3,1'-cyclopropane]-2-one|CFI-400945 free base|(1R,2S)-2-{3-[(E)-2-(4-{[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl}phenyl)ethen-1-yl]-1Hindazol-6-yl}-5'-methoxyspiro[cyclopropane-1,3'-indol]-2'(1'H)-one|(2'S,3R)-2'-[3-[(E)-2-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5-methoxyspiro[1H-indole-3,1'-cyclopropane]-2-one|ocifisertib|Spiro(cyclopropane-1,3'-(3H)indol)-2'(1'H)-one, 2-(3-((1E)-2-(4-(((2R,6S)-2,6-dimethyl-4-morpholinyl)methyl)phenyl)ethenyl)-1H-indazol-6-yl)-5'-methoxy-, (1R,2S)-|CFI-400945,|CFI-400945|(1R,2S)-2-[3-[(1E)-2-[4-[[(2R,6S)-2,6-Dimethyl-4-morpholinyl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5'-methoxyspiro[cyclopropane-1,3'-[3H]indol]-2'(1'H)-one
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Taille
Allemagne (EU)
USA*
Prix
Qté
1mg
C413779-1mg
—
2 En stock

66,73€

78,01€
Enregistrer 11,28 € (14.46%)
5mg
C413779-5mg
—
2 En stock

198,63€

271,52€
Enregistrer 72,89 € (26.85%)
10mg
C413779-10mg
—
2 En stock

321,84€

417,30€
Enregistrer 95,45 € (22.87%)
25mg
C413779-25mg
—
2 En stock

643,78€

1 013,43€
Enregistrer 369,66 € (36.48%)
50mg
C413779-50mg
—
2 En stock

1 029,05€

1 713,70€
Enregistrer 684,65 € (39.95%)
100mg
C413779-100mg
—
2 En stock

1 983,56€

2 571,89€
Enregistrer 588,33 € (22.88%)
Enter a quantity for the sizes you want to add.

Vue d’ensemble

Information

CFI-400945 CFI-400945 is an orally active, potent and selective polo-like kinase 4(PLK4) inhibitor with Ki value of 0.26 nM.


Targets

PLK4 (Cell-free assay); TrkA (Cell-free assay); TrkB (Cell-free assay); Tie-2 (Cell-free assay); Aurora B (Cell-free assay) 16539,2.8 nM; 6 n


In vitro

CFI-400945 is a potent, orally active antitumor agent with the IC50 and Ki values of 2.8 and 0.26 nM, respectively. No significant inhibition against PLKs 1-3 is observed for CFI-400945 at a concentration of 50 μM. CFI-400945 can attenuate the growth of breast cell line, as well as other tumor cell lines significantly. CFI-400945 selectively inhibits PLK4 in cells, but also has certain activity against AURKB, TRKA, TRKB and Tie2/TEK (only 10 kinases showed more than 50% inhibition among 290 kinases). The cytokinesis failure and subsequent polyploidization by CFI-400945 treatment indicate that the cell death in cancer cell lines is at least partly achieved through inhibition of AURKB. No significant inhibition is observed for PLKs 1-3 (IC50s > 50 μM) probably due to the most divergent structure of PLK4 compared to other polo-like kinases 1-3. Cancer cells treated with CFI-400945 exhibit effects consistent with PLK4 kinase inhibition, including dysregulated centriole duplication, mitotic defects, and cell death.


In vivo

CFI-400945 is well tolerated in breast cancer xenograft models, in particular those deficient in the tumor suppressor PTEN. Upon intermittent oral dosing, in a mouse model of colon cancer, CFI-400945 is an effective inhibitor of HCT116 tumor growth and was well tolerated. CFI-400945 is absorbed rapidly after oral administration, reaching maximum plasma concentrations (Cmax) of 0.25-11.68 μg/mL for the doses tested (3.75-104 mg/kg). CFI-400945 can inhibit the growth of a range of tumor types and may be effective in a clinical setting even in advanced tumors. Following oral administration of efficacious doses of CFI-400945 in mice, plasma levels of CFI-400945 are sustained and remained above both the EC50 value for half-maximal inhibition of cellular PLK4 autophosphorylation and growth inhibition GI50 values for 24 hr. Moreover, CFI-400945 demonstrates dose-dependent antitumor activity. Analysis of xenograft tumors from mice treated with an efficacious dose of CFI-400945 shows a pharmacodynamic effect that is suggestive of complete rather than partial inhibition of PLK4 kinase activity.


Cell Research(from reference)

Cell lines:MDA-MB-468, MCF-7, HCC1954, MDA-MB-231, SKBr-3, Cal-51, and BT-20 breast cancer cells 

Concentrations:10 nM to 50 μM 

Incubation Time:5 d 

Spécifications

Synonymes
CFI-400945 (free base) | (1R,2S)-2-(3-((E)-4-(((2R,6S)-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one | (1r,2s)-2-(3-((e)-4-(((2r,6s)-2,6-dimethyl morpholino)methyl)styryl)-1h-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one | Spiro[cyclopropane-1,3'-[3H]indol]-2'(1' Afficher plus
Spécifications et pureté
Moligand™, ≥97%
Mécanismes biochimiques et physiologiques
CFI-400945 is an orally active, potent and selective polo-like kinase 4(PLK4) inhibitor with Ki value of 0.26 nM.
Conditions de stockage de stockage
Store at -20°C
Expédié en
Ice chest + Ice pads
Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.
Grade
Moligand™
Type d'action
INHIBITOR
Mécanisme d'action
Inhibitor of polo like kinase 4
Pureté
≥97%
Noms et identifiants
Pubchem Sid
Pubchem Sid Url
https://pubchem.ncbi.nlm.nih.gov/substance/504771684
SMILES
CC1CN(CC(O1)C)CC2=CC=C(C=C2)C=CC3=NNC4=C3C=CC(=C4)C5CC56C7=C(C=CC(=C7)OC)NC6=O
IUPAC Name
(2'S,3R)-2'-[3-[(E)-2-[4-[[(2R,6S)-2,6-dimethylmorpholin-4-yl]methyl]phenyl]ethenyl]-1H-indazol-6-yl]-5-methoxyspiro[1H-indole-3,1'-cyclopropane]-2-one
InChIKey
DADASRPKWOGKCU-FVTQAUBDSA-N
InChI
1S/C33H34N4O3/c1-20-17-37(18-21(2)40-20)19-23-6-4-22(5-7-23)8-12-29-26-11-9-24(14-31(26)36-35-29)28-16-33(28)27-15-25(39-3)10-13-30(27)34-32(33)38/h4-15,20-21,28H,16-19H2,1-3H3,(H,34,38)(H,35,36)/b12-8+/t20-,21+,28-,33-/m0/s1
Isomères SMILES
C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O
PubChem CID
58486178
Poids moléculaire
534.65

Données avancées

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassOrganoheterocyclic compounds
ClasseBenzopyrazoles
SubclassIndazoles
Intermediate Tree Nodes Not available
Direct ParentIndazoles
Alternative Parents Indolines  Anisoles  Benzylamines  Phenylmethylamines  Styrenes  Alkyl aryl ethers  Aralkylamines  Morpholines  Heteroaromatic compounds  Pyrazoles  Lactams  Trialkylamines  Amino acids and derivatives  Secondary carboxylic acid amides  Oxacyclic compounds  Dialkyl ethers  Azacyclic compounds  Organic oxides  Hydrocarbon derivatives  Carbonyl compounds  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents Indazole - Indole or derivatives - Dihydroindole - Benzopyrazole - Benzylamine - Anisole - Phenol ether - Phenylmethylamine - Styrene - Aralkylamine - Alkyl aryl ether - Benzenoid - Morpholine - Monocyclic benzene moiety - Oxazinane - Heteroaromatic compound - Azole - Pyrazole - Secondary carboxylic acid amide - Lactam - Carboxamide group - Amino acid or derivatives - Tertiary amine - Tertiary aliphatic amine - Oxacycle - Ether - Azacycle - Dialkyl ether - Carboxylic acid derivative - Organic nitrogen compound - Carbonyl group - Organonitrogen compound - Organooxygen compound - Hydrocarbon derivative - Organic oxide - Organic oxygen compound - Amine - Aromatic heteropolycyclic compound
DescriptionThis compound belongs to the class of organic compounds known as indazoles. These are compounds containing an indazole, which is structurally characterized by a pyrazole fused to a benzene.
External Descriptors Not available
Structure 3D
Modèle de structure chimique interactif





Cibles associées (humaines)
CYP2C9 Tchem Cytochrome P450 2C9 (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
TEK Tclin Angiopoietin-1 receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
PLK4 Tchem Serine/threonine-protein kinase PLK4 (6 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
NTRK2 Tclin BDNF/NT-3 growth factors receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
NTRK1 Tclin High affinity nerve growth factor receptor (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
Certificats (CoA, COO, BSE/TSE et tableau d'analyse)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

7 results found

Lot NumberCertificate TypeDateArticle
C2624008C2624008Certificate of AnalysisApr 07, 2026 C413779
K2212319K2212319Certificate of AnalysisAug 12, 2025 C413779
K2212324K2212324Certificate of AnalysisAug 12, 2025 C413779
K2212329K2212329Certificate of AnalysisAug 12, 2025 C413779
K2212331K2212331Certificate of AnalysisAug 12, 2025 C413779
K2212336K2212336Certificate of AnalysisAug 12, 2025 C413779
K2212358K2212358Certificate of AnalysisAug 12, 2025 C413779
Propriétés chimiques et physiques
SolubilitéSolubility (25°C) In vitro DMSO: 100 mg/mL warmed with 50ºC Water: bath (187.03 mM); Ethanol: 100 mg/mL (187.03 mM); Water: Insoluble;
Poids moléculaire534.6
XLogP34.700
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count5
Rotatable Bond Count6
Exact Mass534.263 Da
Monoisotopic Mass534.263 Da
Topological Polar Surface Area79.500 Ų
Heavy Atom Count40
Formal Charge0
Complexity942.000
Isotope Atom Count0
Defined Atom Stereocenter Count4
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count1
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds1
Covalently-Bonded Unit Count1
Calculateurs de solution
Avis

Avis des clients

Besoin d'aide pour choisir la qualité ?

Notre guide de sélection des qualités couvre la pureté, le statut du stabilisant et l'adéquation à l'application pour toutes les variantes de notre catalogue.

Voir le guide des qualités Moligand™ →

Souhaitez-vous que nous vous envoyions un message lorsque des réductions seront disponibles?

Me rappeler plus tard

Merci ! Veuillez vérifier votre boîte de réception e-mail pour confirmer.

Oups ! Les notifications sont désactivées.